191 related articles for article (PubMed ID: 3067007)
1. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
[No Abstract] [Full Text] [Related]
2. [Transplantation of allogeneic bone marrow treated in vitro with Campath-1 monoclonal antibody].
Chapuis B; Helg C; Maurice P; Wyss M; Pipard G; Irlé C; Jeannet M
Schweiz Med Wochenschr; 1985 Oct; 115(43):1521-2. PubMed ID: 3909387
[TBL] [Abstract][Full Text] [Related]
3. T-cell depletion with the monoclonal antibody Campath 1 to prevent graft-versus-host disease in ten high-risk adult patients.
Bandini G; Ricci P; Gobbi M; Tazzari PL; Motta MR; Guardigli C; Rizzi S; Baccarani M; Tura S
Haematologica; 1986; 71(4):307-11. PubMed ID: 3096824
[No Abstract] [Full Text] [Related]
4. [Quantitative determination of human bone marrow T cells following in vitro depletion by Campath-1 monoclonal antibody].
Irlé C; Kaestli M; Chapuis B; Jeannet M
Schweiz Med Wochenschr; 1985 Oct; 115(43):1517-8. PubMed ID: 3909385
[TBL] [Abstract][Full Text] [Related]
5. The use of monoclonal antibodies in graft versus host disease prevention.
Brenner MK; Grob JP; Prentice HG
Haematologia (Budap); 1986; 19(3):167-76. PubMed ID: 3536685
[TBL] [Abstract][Full Text] [Related]
6. [Application of monoclonal antibodies to bone marrow transplantation].
Morishima Y
Gan To Kagaku Ryoho; 1988 May; 15(5):1693-701. PubMed ID: 3285796
[TBL] [Abstract][Full Text] [Related]
7. Depletion of T-lymphocytes in donor marrow with pan-T monoclonal antibodies and complement for prevention of acute graft-versus-host disease: a pilot study on 29 patients.
Herve P
J Natl Cancer Inst; 1986 Jun; 76(6):1311-6. PubMed ID: 3520074
[TBL] [Abstract][Full Text] [Related]
8. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
Apperley JF; Jones L; Hale G; Waldmann H; Hows J; Rombos Y; Tsatalas C; Marcus RE; Goolden AW; Gordon-Smith EC
Bone Marrow Transplant; 1986 May; 1(1):53-66. PubMed ID: 3332120
[TBL] [Abstract][Full Text] [Related]
10. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies].
Hervé P; Flesch M
Nouv Rev Fr Hematol (1978); 1986; 28(2):97-105. PubMed ID: 2942838
[TBL] [Abstract][Full Text] [Related]
11. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
12. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
Slavin S; Or R; Naparstek E; Weiss L; Mumcuoglu M; Weshler Z; Brautbar H; Cividalli G; Glikson M; Hale G
Transplant Proc; 1987 Feb; 19(1 Pt 3):2614-5. PubMed ID: 3274569
[No Abstract] [Full Text] [Related]
14. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
Henslee PJ; Byers VS; Jennings CD; Marciniak E; Thompson JS; Macdonald JS; Romond EH; Messino MJ; Scannon PJ
Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413
[No Abstract] [Full Text] [Related]
15. [In vitro manipulation of bone marrow cells for bone marrow transplantation].
Morishima Y
Gan To Kagaku Ryoho; 1988 Nov; 15(11):3034-43. PubMed ID: 3056275
[TBL] [Abstract][Full Text] [Related]
16. Perspectives in the prevention and treatment of acute graft versus host disease.
Herve P
Bone Marrow Transplant; 1991; 7 Suppl 2():117-9. PubMed ID: 1715225
[No Abstract] [Full Text] [Related]
17. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect.
Henslee PJ; Thompson JS; Romond EH; Doukas MA; Metcalfe M; Marshall ME; MacDonald JS
Transplant Proc; 1987 Feb; 19(1 Pt 3):2701-6. PubMed ID: 3547948
[No Abstract] [Full Text] [Related]
18. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation.
Champlin R; Gajewski J; Feig S; Giorgi J; Lyddane N; Lee K; Schmidt I; Winston D; Ho W; Reichert T
Transplant Proc; 1989 Feb; 21(1 Pt 3):2947-8. PubMed ID: 2495694
[No Abstract] [Full Text] [Related]
19. Graft versus host disease prophylaxis today.
Martelli MF; Aversa F
Bone Marrow Transplant; 1991; 7 Suppl 2():112-6. PubMed ID: 1908726
[No Abstract] [Full Text] [Related]
20. Perspectives in marrow graft T-cell depletion in allogeneic matched related bone marrow transplantation.
Tiberghien P; Hervé P
Transfus Sci; 1992; 13(4):443-54. PubMed ID: 10147740
[No Abstract] [Full Text] [Related]
[Next] [New Search]
